FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W80549923> ?p ?o ?g. }

• W80549923 startingPage "1508" @default.
• W80549923 abstract "Treatment of severe pain often requires use of an opioid analgesic such as morphine, their use is limited by serious side effects including tolerance, physical dependence, respiratory depression and addiction liability. Numerous opiates have been synthesized in an effort to obtain analgesics that are free of such side effects.1Opioids bind to specific neuronally located proteins which initiate biologic responses. Opioid receptors were first discovered in mammalian brain and belong to the rohdopsin subfamily in the superfamily of over 1000 G protein-coupled receptors.2 Three opioid receptor types, kappa (κ), delta (δ) and mu (μ),3–5 differ in their distribution and ligand binding, and were identified through pharmacological and physiological studies using selective ligands.Our objective is to identify long-acting opioid receptor ligands useful for the treatment of cocaine abuse by the synthesis and evaluation of opioid receptor binding affinities of a series carbamate analogues of morphinans. Earlier studies have shown that the basic nitrogen and a phenol moiety were necessary for narcotic analgesics to bind to its opioid receptors.6 As is the case for morphine derivatives, the phenolic hydroxyl group in morphinan contributes to analgesic activity, which is also a potential site for metabolism, conjugation, and excretion via O-glucuronidation resulting in low oral bioavailability and short duration of action.1 An approach to improving the pharmacological properties of analgesics such as morphine is to modify the phenolic hydroxy function.To develop additional insight into the SAR surrounding the 3-position of morphinan, we wished to modify the 3-OH function of morphinan. The carbamate group was introduced because it is a structure of medium polarity, capable of forming hydrogen bonds as donor and acceptor.7–9 Ideally, these modified compounds would have a longer duration of action and better bioavailability. We report a series of morphinans where the 3-OH was modified by incorporating the carbamate function at the 3 position of the morphinan template.The levoratory morphinans (2a, 3a) were prepared from commercially available (−)-3-hydroxy-N-methylmorphinan tartrate (levorphanol) 1a which was converted to the free base and N-demethylated 10–12 to yield the normorphinan. Alkylation with cyclopropylmethyl or cyclobutylmethyl bromide led to the (−)-N-substituted morphinan characterized as their crystalline mandelate salts (2a and 3a) respectively.A series of carbamates were prepared using morphinans (1a, 2a, 3a) as starting materials. The carbamates were made in yields ranging from 55–90% by treating the morphinans (1a, 2a, 3a) with the corresponding commercially available aryl or alkyl isocyanates.Affinity and selectivity of the synthesized ligands were evaluated for their affinity at and selectivity for μ, δ and κ opioid receptors with Chinese hamster ovary (CHO) cell membranes stably expressing one type of the human opioid receptors. The data are summarized in Table 1. For comparison purposes, opioid binding affinity data for levorphanol (1a), cyclorphan (2a) and butorphan (3a) are also included.11Table 1Ki Values For The Inhibition of μ, δ and κ Opioid Binding to Chinese Hamster Ovary Membrane by Carbamate OpioidsFrom the data shown in Table 1, the binding affinities of the carbamate derived opioids were generally lower than the binding affinities of the phenol precursors. It is noteworthy that the phenyl carbamate analogs (2d and 3d) retained the same high affinity (Ki = 0.046 nM~0.051nM) at the κ receptor, and a 2 fold decrease at μ for 2d and a 2 fold increase at μ for 3d were observed when compared with cyclorphan (2a) and butorphan (3a).The methyl carbamate analogues (1b, 2b and 3b), compared to the phenolic precursors, showed 1.4 – 100 fold decrease in affinity at κ, 3 – 22 fold decrease at δ and 5 – 85 fold decrease at the μ receptor and compound 3b displayed a good selectivity for κ versus δ receptors. Similarly, appreciable decreases in affinity were observed in the ethyl carbamate analogues (1c, 2c and 3c) compared to the parent compounds. Compared to phenol 2a and 3a, the benzyl carbamate isomer 2e and 3e displayed slightly lower affinity (4 fold) at κ, at μ and δ receptors. All N-cyclopropylmethyl derivatives retained κ/μ selectivity, while all N-cyclobutylmethyl derivatives showed higher μ selectivity over κ receptors compared to butorphan (3a).It is interesting to note that compound 2e (benzyl carbamate of cyclorphan 2a) displayed almost identical affinities at all three opioid receptors as the analogue ethyl carbamate of cyclorphan 2c, while the benzyl carbamate of butorphan 3e displayed higher affinities than the ethyl carbamate of butorphan 3c at all three receptors.The relative efficacy of these morphinan ligands, 1b, 1c, 2b–2e and 3b–3e, compared with levorphanol (1a), cyclorphan (2a) and butorphan (3a) were selected for the [35S]GTPγS assay. Table 2 shows the agonist and antagonist properties of these ligands in stimulating [35S]GTPγS binding mediated by the κ opioid receptor.Table 2Agonist and Antagonist Properties of Compounds in Stimulating [35S]GTPγS Binding Mediated by the κ Opioid ReceptoraLigands 2c, 2d, 2e and 3e produced high maximal stimulation of [35S]GTPγS binding (Emax) comparable to that of selective agonist U50,488, while ligands 1b, 2b, 3b and 3d produced similar maximal stimulation comparable to that of the compounds 2a and 3a, but less than that of selective agonist U50,488.The EC50 values of these ligands are similar which substantially correlates with the Ki values obtained for the compounds in the binding assays with [3H]U69,593. Similar to cyclorphan (2a) and butorphan (3a), these ligands did not inhibit U50,488-stimulated [35S]GTPγS, which suggested that most of these ligands were full κ agonists.The properties of these ligands in stimulating [35S]GTPγS binding mediated by the μ opioid receptor are shown in Table 3.Table 3Agonist and Antagonist Properties of Compounds in Stimulating [35S]GTPγS Binding Mediated by the μ Opioid ReceptoraLigands 1b, 2b and 3b produced maximal stimulation of [35S]GTPγS binding mediated by μ receptor comparable to that of the parent compound cyclorphan (2a) and butorphan (3a) and no inhibition of DAMGO-stimulated [35S]GTPγS binding. These data indicated that 1b, 2b and 3b were μ agonists. Ligands 2c, 2d and 2e had the lowest maximal stimulation of [35S]GTPγS binding and the highest maximal inhibition (Imax) of the DAMGO-stimulated [35S]GTPγS binding indicating that ligands 2c, 2d and 2e are μ antagonists with weak agonistic activity at the μ receptors. Compounds 3c, 3d and 3e produced lower maximal inhibition (Imax) of the DAMGO-stimulated [35S]GTPγS binding than the carbamates of the cyclorphan (ligands 2c, 2d, and 2e). These data indicated that ligands 3c, 3d and 3e are weak μ agonists and antagonists.The preliminary assay for agonist and antagonist properties of these ligands in stimulating [35S]GTPγS binding mediated by the κ opioid receptor illustrated that all of these ligands were κ agonists, however compounds 1b, 2b and 3b were agonists at the μ receptor whereas compounds 2c, 2d, 2e, 3c, 3d and 3e were both agonists and antagonists at the μ receptor.A series of carbamate analogues were synthesized from levorphanol (1a), cyclorphan (2a) or butorphan (3a) and evaluated in-vitro by their binding affinity at μ, δ and κ opioid receptors. The binding affinities of the carbamate derived opioids were generally lower than the binding affinities of the phenol precursors. Phenyl carbamate derivatives 2d and 3d showed the highest binding affinity for κ receptor, and increased affinity at μ for 3d.Functional activities of these compounds were measured in the [35S]GTPγS binding assay, indicating that all of these ligands were κ agonists while, compounds 1b, 1c, 2b and 3b were μ agonists, and compounds 2c, 2d, 2e, 3c, 3d and 3e were μ agonist/antagonist. Such carbamate derivatives may be useful for the development of longer-acting analgesics as well as medications for drug abuse." @default.
• W80549923 created "2016-06-24" @default.
• W80549923 creator A5001580309 @default.
• W80549923 creator A5036697104 @default.
• W80549923 creator A5049508440 @default.
• W80549923 creator A5067802380 @default.
• W80549923 date "2007-03-15" @default.
• W80549923 modified "2023-09-23" @default.
• W80549923 title "High Affinity of Carbamate Analogues of Morphinan atOpioid Receptors" @default.
• W80549923 doi "https://doi.org/10.1016/j.bmcl.2007.01.03" @default.
• W80549923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1853345" @default.
• W80549923 hasPublicationYear "2007" @default.
• W80549923 type Work @default.
• W80549923 sameAs 80549923 @default.
• W80549923 citedByCount "0" @default.
• W80549923 crossrefType "journal-article" @default.
• W80549923 hasAuthorship W80549923A5001580309 @default.
• W80549923 hasAuthorship W80549923A5036697104 @default.
• W80549923 hasAuthorship W80549923A5049508440 @default.
• W80549923 hasAuthorship W80549923A5067802380 @default.
• W80549923 hasConcept C170493617 @default.
• W80549923 hasConcept C185592680 @default.
• W80549923 hasConcept C2779303437 @default.
• W80549923 hasConcept C55493867 @default.
• W80549923 hasConcept C71240020 @default.
• W80549923 hasConceptScore W80549923C170493617 @default.
• W80549923 hasConceptScore W80549923C185592680 @default.
• W80549923 hasConceptScore W80549923C2779303437 @default.
• W80549923 hasConceptScore W80549923C55493867 @default.
• W80549923 hasConceptScore W80549923C71240020 @default.
• W80549923 hasIssue "6" @default.
• W80549923 hasLocation W805499231 @default.
• W80549923 hasOpenAccess W80549923 @default.
• W80549923 hasPrimaryLocation W805499231 @default.
• W80549923 hasRelatedWork W1063528934 @default.
• W80549923 hasRelatedWork W1464190262 @default.
• W80549923 hasRelatedWork W1531305778 @default.
• W80549923 hasRelatedWork W1915272650 @default.
• W80549923 hasRelatedWork W1942647961 @default.
• W80549923 hasRelatedWork W1970149395 @default.
• W80549923 hasRelatedWork W1994878819 @default.
• W80549923 hasRelatedWork W1998108947 @default.
• W80549923 hasRelatedWork W2003454699 @default.
• W80549923 hasRelatedWork W2003574853 @default.
• W80549923 hasRelatedWork W2060003313 @default.
• W80549923 hasRelatedWork W2068038560 @default.
• W80549923 hasRelatedWork W2070714099 @default.
• W80549923 hasRelatedWork W2085672169 @default.
• W80549923 hasRelatedWork W2089958917 @default.
• W80549923 hasRelatedWork W2101858338 @default.
• W80549923 hasRelatedWork W2360783516 @default.
• W80549923 hasRelatedWork W2800337447 @default.
• W80549923 hasRelatedWork W2951349405 @default.
• W80549923 hasRelatedWork W2186233766 @default.
• W80549923 hasVolume "17" @default.
• W80549923 isParatext "false" @default.
• W80549923 isRetracted "false" @default.
• W80549923 magId "80549923" @default.
• W80549923 workType "article" @default.